Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why AVEO Pharmaceuticals Shares Were Eviscerated

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of cancer therapeutics company AVEO Pharmaceuticals (NASDAQ: AVEO  ) absolutely imploded, losing as much as 57% – and dropping as much as 70% for the week at one point – after its metastatic renal cancer carcinoma drug, Tivozanib, failed to win the backing of the Food and Drug Administrations' panel.

So what: In midday trading, AVEO and development partner Astellas Pharma reported that the FDA panel had voted 13-1 that Tivozanib had not demonstrated a favorable benefit-to-risk evaluation in treating advanced kidney cancer. AVEO's CEO, Tuan Ha-Ngoc, noted his discouragement with the FDA panels' findings, but plans to work closely with the FDA to improve upon what it felt Tivozanib lacked. If you recall, Tivozanib demonstrated a statistically significant progression-free survival benefit over Onyx Pharmaceuticals (UNKNOWN: ONXX.DL  ) and Bayer's (NASDAQOTH: BAYRY  ) Nexavar in trials, but fell short of Nexavar in terms of median overall survival, which perplexed many.

Now what: Although the Food and Drug Administration isn't required to follow the recommendation of its panel, I'd find it difficult for them to approve Tivozanib here. I'm not saying the drug is a complete loss, as it clearly showed a benefit in PFS. However, there doesn't seem to be any way around the idea of AVEO having to run another costly trial to confirm that the median overall survival data was a fluke. Don't write Tivozanib off just yet, but I think it's time to push its development perhaps a year or two down the road.

Craving more input? Start by adding AVEO Pharmaceuticals to your free and personalized Watchlist so you can keep up on the latest news with the company.

While you can certainly make huge gains in biotechs like AVEO, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2404798, ~/Articles/ArticleHandler.aspx, 9/30/2016 4:41:38 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,308.15 164.70 0.91%
S&P 500 2,168.27 17.14 0.80%
NASD 5,312.00 42.85 0.81%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/30/2016 4:00 PM
AVEO $0.89 Up +0.00 +0.01%
AVEO Pharmaceutica… CAPS Rating: **
BAYRY $100.50 Up +2.54 +2.59%
Bayer AG (ADR) CAPS Rating: ***
ONXX.DL $0.00 Down +0.00 +0.00%
Onyx Pharmaceutica… CAPS Rating: **